spacer
home > pmps > autumn 2008 > oral liquid dispensation:
technology evolution
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Oral Liquid Dispensation:
Technology Evolution

One of the most common ways of dispensing a liquid medicine has been the spoon throughout history; this will inevitably continue for some time. Spoons in Europe commonly come in three sizes: coffee size (5ml), dessert size (10ml) and soup size (15ml). Spoons were introduced to French tables during the fourteenth century but without any standard volume; the different recognised sizes were defined later.

The origin of using spoons for medicine dispensation seems to be the desire to achieve consistent volume with an everyday utensil. The purpose of this article is not to give a detailed history of spoons, but simply to note that even now we are still using a very old method for medicine dispensation.

FROM THE SPOON TO THE SYRINGE

The main benefit of the spoon for the pharmaceutical industry is the simplicity of the device, adding no additional cost for product development, device manufacturing or specific packaging. Furthermore, the advantage for patients is...

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Cedric Marmonier is the associated Managing Director of Rovipharm SAS. After working as Technical Manager in weaving machine manufacturing, and as a Business Manager with various plastic injection companies, Cedric first worked with plastic injection in 2002, and founded Rovipharm SAS in January 2006 in association with Mrs Emanuelle Boizet. His department is dedicated to the clean room production of pharmaceutical plastic product injection. As Business and Marketing Manager, Cedric brings his strong experience in plastic injection and business management.
spacer
Cedric Marmonier
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Arcis Biotechnology appointments Professor Steve Howell as Non-Executive Chairman

Daresbury, UK, 24 July 2019: Arcis Biotechnology (“Arcis”), the nucleic acid sample preparation solution provider, today announced it has appointed Professor Steve Howell as Non-Executive Chairman of its Board of Directors. Steve takes over the position from Paul Foulger, who was serving as Chairman on an interim basis on behalf of the Board.
More info >>

White Papers

Orthogonal Approaches for the Analysis of Protein Sequence and Post Translational Modifications of a Monoclonal Antibody

RSSL

Monoclonal antibodies are an important class of biopharmaceuticals. They are expressed from living cells and therefore, are subject to complex biochemical pathways. Not all of these pathways are fully understood and many are known to be sensitive to subtle environmental changes during production. These changes may affect the final biopharmaceutical sequence, structure and post-translational modifications. This is in addition to any changes that may occur during subsequent purification. This means that the final product from one batch may be subtly different from another batch. Furthermore, each batch is a heterogeneous mix of similar molecules. Analysis of the degree of batch-tobatch variation, and batch heterogeneity, is therefore, very important to establish in order to be confident that the drug is safe and effective for medicinal use.
More info >>

 
Industry Events

SMi Presents the 4th Annual: Highly Potent Active Pharmaceutical Ingredients (HPAPI)

11-13 May 2020, Copthorne Tara Hotel, London, UK

SMi is delighted to announce its 4th Annual Highly Potent Active Pharmaceutical Ingredients conference coming to London on the 11th – 12th May 2020. HPAPI 2020 conference focuses on the growing landscape driven by the demand for highly potent drugs in oncology, diabetes and autoimmune disease treatment. This event will address the biggest challenges the industry is facing with regards to determining toxicology limits, assessing hazards, implementing risk procures, translating risk assessment into facility engineering, preventing and dealing with cross-contamination and adhering to GMP regulatory guidelines.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement